Unknown Analyst

Welcome back to the Bank of America Healthcare Conference. Our next session is with Gilead Sciences. Sitting next to me on stage is Johanna Mercier, who is Chief Commercial Officer and Head of Corporate Affairs.

Johanna, thank you for making the trip out West to see us today.

Johanna Mercier
Chief Commercial & Corporate Affairs Officer

Easy trip. Thank you. Thanks for having me.

Unknown Analyst

So for the few people who don't know Gilead as well as some of the other people do, just give us a quick overview of the company and its focus areas, and then we can go into more detailed questions.

Johanna Mercier
Chief Commercial & Corporate Affairs Officer

Okay. Great. So Gilead Sciences is still a young company. It's just coming on to about 40 years or so and one that is specialized across 3 therapeutic areas, some more developed than others, but HIV, oncology and inflammation.

And the foundational piece of the business is really in HIV, both treatment and prevention and really building the oncology franchise with both solid tumor as well as liquid tumors. And then, of course, a little bit earlier pipeline in the inflam space, although we do have a PBC seladelpar with LIBALVI that's also doing very well in the marketplace that just launched about 2 years ago now coming up to 2 years.

So the organization is really building on a strategy that it set forth about 6 years or so ago of that diversification and delivering against it. We just announced our earnings just last Thursday with a really strong start to 2026. We